Post Earnings Coverage as ResMed Revenue Increased 17%

Upcoming AWS Coverage on Edwards Lifesciences Post-Earnings Results

LONDON, UK / ACCESSWIRE / January 30, 2017 / Active Wall St. announces its post-earnings coverage on ResMed Inc. (NYSE: RMD). The Company disclosed its second quarter fiscal 2017 financial results on January 23, 2017. The developer of treatments for sleep-disorder breathing reported a top- and bottom-line beat. Register with us now for your free membership at:

http://www.activewallst.com/register/

One of ResMed’s competitors within the Medical Appliances & Equipment space, Edwards Lifesciences Corp. (NYSE: EW), announced on January 17, 2017, its operating results for the quarter ended December 31, 2016, after the market closes on Wednesday, February 01, 2017, and will host a conference call at 5:00 p.m. ET that day to discuss those results. AWS will be initiating a research report on Edwards Lifesciences in the coming days.

Today, AWS is promoting its earnings coverage on RMD; touching on EW. Get our free coverage by signing up to:

http://www.activewallst.com/registration-3/?symbol=RMD

http://www.activewallst.com/registration-3/?symbol=EW

Earnings Reviewed:

For its quarter ended December 31, 2016, ResMed reported revenue of $530.4 million, a 17% increase compared to the same period of the prior year. Excluding the contribution from the Brightree business acquired in April 2016, the Company’s revenue for the reported quarter was $496.6 million, up by 9%. The reported figure surpassed analysts’ consensus estimates of $522 million.

ResMed’s gross margin in Q2 FY17 was 58.3%, which was higher than the prior year’s quarter gross margin of 58.1%. The improvement in gross margin was attributed to manufacturing and procurement efficiencies and an incremental contribution from the Brightree acquisition, partly offset by changes in product mix and declines in average selling prices. The Company’s income from operations for Q2 FY17 was $96.9 million, down 10% compared with the quarter ended December 31, 2015. Non-GAAP income from operations for the reported quarter was $131.6 million, a 13% increase on a y-o-y basis.

ResMed’s net income for Q2 FY17 totaled $76.7 million, down 20% compared to the same period last year. GAAP diluted earnings per share for the reported quarter decreased 21% to $0.54. Earnings, adjusted for costs related to mergers and acquisitions and amortization costs was $103.3 million, up 1% on a y-o-y basis, while on per share basis it totaled $0.73 per share, consistent with the same period of the prior year. ResMed’s adjusted earnings figure topped Wall Street’s expectations of $0.70 per share.

Segment Results:

On a geographical basis, ResMed’s Q2 FY17 revenue in the Americas was $326.8 million, a 21% increase over the same period of the prior year. This included Brightree’s revenue of $33.8 million. Excluding Brightree, revenue in the Americas totaled $293.0 million, up 9% on a y-o-y basis. Revenue in combined EMEA and APAC was $203.6 million, an increase of 13% on a constant currency basis compared to the same period of the prior year.

Globally, in constant currency terms, ResMed’s device sales increased by 17% in Q2 FY17, while masks and other increased by 2% over the prior year comparable quarter. ResMed’s Americas device sales were $154.3 million, an increase of 13% on a y-o-y basis. Masks and other sales were $138.6 million, an increase of 4% over Q2 FY16. Device sales in combined EMEA and Asia/Pacific were $146.7 million, an increase of 21% on a constant currency basis compared to the same period of the prior year. Masks and other sales in the region were $57 million, down 7% over prior year’s corresponding quarter, or in constant currency terms, a decrease of 4%.

Balance Sheet & Cash Flow:

For Q2 FY17, ResMed generated operating cash flow of $119.9 million. The Company’s capital expenditure for the reported quarter was $14.7 million. Depreciation and amortization for Q2 FY17 totaled $27.7 million. As of December 31, 2016, ResMed had approximately $1.2 billion in gross debt and $318 million in net debt. The Company’s total assets as of December 31, 2016, were $3.3 billion and net equity was $1.7 billion. The ResMed’s board of directors declared a quarterly cash dividend of $0.33 per share. The dividend will have a record date of February 09, 2017, payable on March 16, 2017.

Stock Performance:

At the close of trading session on January 27, 2017, ResMed’s stock price slightly declined 0.37% to end the day at $68.14. A total volume of 682.40 thousand shares were exchanged during the session. The Company’s share price has gained 23.69% in the past twelve months and 9.81% on a YTD basis. The stock currently has a market cap of $9.59 billion. The Company’s shares are trading at a PE ratio of 27.71 and have a dividend yield of 1.94%.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY:

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING:

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT:

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street

ReleaseID: 453775